Stock Track | Inari Medical Soars on Strong Q3 Results, Upbeat Guidance

Stock Track10-29

Shares of Inari Medical, Inc. (NASDAQ: NARI) surged 12.08% on October 29, 2024, after the medical device company reported impressive third-quarter results and raised its full-year revenue guidance.

For the third quarter ended September 30, 2024, Inari Medical posted revenue of $153.4 million, a 21.4% increase compared to the same period last year. The strong revenue growth was driven by an expansion in sales territories, opening of new accounts, increased adoption of the company's procedures, global commercial expansion, and the introduction of new products. The revenue figure also surpassed analysts' expectations.

Inari Medical raised its full-year 2024 revenue guidance to a range of $601.5 million to $604.5 million, reflecting an increase of $3.5 million at the midpoint from its prior outlook. The company also expects to achieve sustained operating profitability in the first half of 2025, indicating an improved profitability outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128052470?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 21:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128052470","market":"us","top_or_hot":-1,"title":"Stock Track | Inari Medical Soars on Strong Q3 Results, Upbeat Guidance","media":"Stock Track","content":"<p>Shares of Inari Medical, Inc. (NASDAQ: NARI) surged 12.08% on October 29, 2024, after the medical device company reported impressive third-quarter results and raised its full-year revenue guidance.</p>\n\n<p>For the third quarter ended September 30, 2024, Inari Medical posted revenue of $153.4 million, a 21.4% increase compared to the same period last year. The strong revenue growth was driven by an expansion in sales territories, opening of new accounts, increased adoption of the company's procedures, global commercial expansion, and the introduction of new products. The revenue figure also surpassed analysts' expectations.</p>\n\n<p>Inari Medical raised its full-year 2024 revenue guidance to a range of $601.5 million to $604.5 million, reflecting an increase of $3.5 million at the midpoint from its prior outlook. The company also expects to achieve sustained operating profitability in the first half of 2025, indicating an improved profitability outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Inari Medical Soars on Strong Q3 Results, Upbeat Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Inari Medical Soars on Strong Q3 Results, Upbeat Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-29 21:37 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Inari Medical, Inc. (NASDAQ: NARI) surged 12.08% on October 29, 2024, after the medical device company reported impressive third-quarter results and raised its full-year revenue guidance.\n...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NARI","symbol_name":"Inari Medical, Inc.","start_time":0,"source_url":"","article_id":"1128052470","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128052470","pubTimestamp":1730209066,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Inari Medical, Inc.  surged 12.08% on October 29, 2024, after the medical device company reported impressive third-quarter results and raised its full-year revenue guidance.For the third quarter ended September 30, 2024, Inari Medical posted revenue of $153.4 million, a 21.4% increase compared to the same period last year. The strong revenue growth was driven by an expansion in sales territories, opening of new accounts, increased adoption of the company's procedures, global commercial","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NARI":"Inari Medical, Inc."},"translate_title":"股票赛道伊那里医疗(Inari Medical)因强劲的第三季度业绩和乐观的指引而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NARI":1},"content_text":"Shares of Inari Medical, Inc. (NASDAQ: NARI) surged 12.08% on October 29, 2024, after the medical device company reported impressive third-quarter results and raised its full-year revenue guidance.\nFor the third quarter ended September 30, 2024, Inari Medical posted revenue of $153.4 million, a 21.4% increase compared to the same period last year. The strong revenue growth was driven by an expansion in sales territories, opening of new accounts, increased adoption of the company's procedures, global commercial expansion, and the introduction of new products. The revenue figure also surpassed analysts' expectations.\nInari Medical raised its full-year 2024 revenue guidance to a range of $601.5 million to $604.5 million, reflecting an increase of $3.5 million at the midpoint from its prior outlook. The company also expects to achieve sustained operating profitability in the first half of 2025, indicating an improved profitability outlook.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128052470"}